[go: up one dir, main page]

WO2000043373A3 - Inhibiteurs de kinase - Google Patents

Inhibiteurs de kinase Download PDF

Info

Publication number
WO2000043373A3
WO2000043373A3 PCT/US2000/001581 US0001581W WO0043373A3 WO 2000043373 A3 WO2000043373 A3 WO 2000043373A3 US 0001581 W US0001581 W US 0001581W WO 0043373 A3 WO0043373 A3 WO 0043373A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
methods
compositions
kinase inhibitors
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/001581
Other languages
English (en)
Other versions
WO2000043373A2 (fr
Inventor
David M Armistead
Jean E Bemis
Daniel Elbaum
Gregory Habgood
Perry M Novak
Joseph J Nunes
Leticia M Toledo-Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kinetix Pharmaceuticals Inc
Original Assignee
Kinetix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinetix Pharmaceuticals Inc filed Critical Kinetix Pharmaceuticals Inc
Priority to CA002359680A priority Critical patent/CA2359680A1/fr
Priority to JP2000594789A priority patent/JP2002535318A/ja
Priority to EP00905700A priority patent/EP1144390A2/fr
Priority to AU27344/00A priority patent/AU768201B2/en
Publication of WO2000043373A2 publication Critical patent/WO2000043373A2/fr
Publication of WO2000043373A3 publication Critical patent/WO2000043373A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des inhibiteurs de kinases, des compositions renfermant ces inhibiteurs et des procédés d'utilisation desdits inhibiteurs et desdites compositions. Ces inhibiteurs et les compositions qui les renferment conviennent pour le traitement de pathologies et de leurs symptômes. L'invention concerne également des procédés de fabrication de composés inhibiteurs de kinases, des méthodes permettant d'inhiber l'activité kinase et des méthodes de traitement de pathologies et de leurs symptômes.
PCT/US2000/001581 1999-01-22 2000-01-21 Inhibiteurs de kinase Ceased WO2000043373A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002359680A CA2359680A1 (fr) 1999-01-22 2000-01-21 Inhibiteurs de kinase
JP2000594789A JP2002535318A (ja) 1999-01-22 2000-01-21 キナーゼ阻害薬
EP00905700A EP1144390A2 (fr) 1999-01-22 2000-01-21 Inhibiteurs de kinase
AU27344/00A AU768201B2 (en) 1999-01-22 2000-01-21 Kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11669799P 1999-01-22 1999-01-22
US60/116,697 1999-01-22

Publications (2)

Publication Number Publication Date
WO2000043373A2 WO2000043373A2 (fr) 2000-07-27
WO2000043373A3 true WO2000043373A3 (fr) 2000-12-28

Family

ID=22368683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001581 Ceased WO2000043373A2 (fr) 1999-01-22 2000-01-21 Inhibiteurs de kinase

Country Status (5)

Country Link
EP (1) EP1144390A2 (fr)
JP (1) JP2002535318A (fr)
AU (1) AU768201B2 (fr)
CA (1) CA2359680A1 (fr)
WO (1) WO2000043373A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
AU2001237041B9 (en) * 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
ES2556946T3 (es) 2000-12-21 2016-01-21 Novartis Ag Pirimidinaminas como moduladores de la angiogénesis
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
EP1487436A4 (fr) 2002-03-08 2009-06-03 Signal Pharm Inc Polytherapie destinee a traiter, prevenir ou gerer des troubles proliferatifs et des cancers
MXPA05005477A (es) 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
RU2418788C2 (ru) * 2005-03-10 2011-05-20 Сги Фармасьютиклз, Инк. Некоторые замещенные амиды, способ их получения и способ их применения
EP1863766B1 (fr) * 2005-03-10 2015-05-20 Gilead Connecticut, Inc. Amides substitues, procede pour les produire et procede pour les utiliser
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PE20081370A1 (es) * 2006-09-11 2008-11-28 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
CA2675558A1 (fr) 2007-02-06 2008-08-14 Novartis Ag Inhibiteurs de la pi3-kinase et procedes de leur utilisation
EP2373636A4 (fr) * 2008-12-05 2012-10-17 Merck Sharp & Dohme Inhibiteurs de la kinase 1 dépendante des phosphoinositides (pdk1)
CN102206207B (zh) * 2011-04-15 2015-05-06 南京邮电大学 4-芳基嘧啶或4-杂环芳基嘧啶化合物发光材料及其制备方法
US9221840B2 (en) 2011-05-17 2015-12-29 Discoverybiomed Inc. Treating protein folding disorders with small molecule CFTR correctors
WO2013046136A1 (fr) 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US20150166520A1 (en) * 2012-07-20 2015-06-18 Merck Sharp & Dohme Corp. Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
AU2013348019A1 (en) 2012-11-20 2015-06-04 Discoverybiomed, Inc. Small molecule bicyclic and tricyclic CFTR correctors
US9676779B2 (en) 2012-11-20 2017-06-13 Discoverybiomed, Inc. Small molecule CFTR correctors
EA028033B1 (ru) 2013-03-14 2017-09-29 Новартис Аг 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантного idh
WO2019055832A1 (fr) * 2017-09-15 2019-03-21 The Regents Of The University Of California Compositions et procédés d'inhibition de la n-smase2
KR102159277B1 (ko) * 2018-11-26 2020-09-23 고려대학교 산학협력단 뇌종양 줄기세포의 세포사멸 유도 활성을 갖는 피리미딘온 유도체 화합물의 용도
CN110105368B (zh) * 2019-05-09 2022-01-07 上海大学 去氧紫杉烷类似物及其制备方法
US20220273658A1 (en) * 2019-09-05 2022-09-01 University Of Houston System Small molecule liver x receptor modulators and uses thereof

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378557A (en) * 1963-06-04 1968-04-16 Searle & Co 5-alkyl-2-amino-3-aminoalkyl-6-aryl-4(3h)-pyrimidinones and congeners
GB2048250A (en) * 1979-03-19 1980-12-10 Upjohn Co 2-amino-6-aryl-4-pyrimidinols and their pharmaceutical uses
US4308272A (en) * 1980-10-03 1981-12-29 The Upjohn Company Process for treating hypertension
GB2107309A (en) * 1981-08-28 1983-04-27 Egyt Gyogyszervegyeszeti Gyar Preparation of 2-amino-4- hydroxy-5-halo-substituted pyrimidine derivatives
GB2158068A (en) * 1984-04-26 1985-11-06 Aston Molecules Ltd Pyrimidine derivative solvate compounds
JPS61205260A (ja) * 1985-03-08 1986-09-11 Zeria Shinyaku Kogyo Kk 新規な２−置換アミノ−６−（２−メトキシフエニ−ル）−４（３ｈ）−ピリミドン誘導体及びその製造法
US4689328A (en) * 1985-12-31 1987-08-25 Research Corporation Process for controlling hyperlipidemia
JPH0331267A (ja) * 1989-06-28 1991-02-12 Morishita Pharmaceut Co Ltd ２―アニリノ―１，６―ジヒドロ―６―オキソ―４―ピリミジンカルボン酸誘導体
WO1997033883A1 (fr) * 1996-03-13 1997-09-18 Smithkline Beecham Corporation Nouveaux composes de pyrimidine utiles dans le traitement de maladies a mediation cytokine
WO1997044326A1 (fr) * 1996-05-23 1997-11-27 F. Hoffmann-La Roche Ag Derives d'aryl pyrimidine
WO1998014504A1 (fr) * 1996-10-04 1998-04-09 Dsm N.V. Polymere supramoleculaire
WO1998018782A1 (fr) * 1996-10-28 1998-05-07 Celltech Therapeutics Limited Derives de 2-pyrimidineamine et procedes de preparation
WO1998025596A2 (fr) * 1996-12-12 1998-06-18 Pharmacia & Upjohn Company Methode de traitement de la sclerose en plaques

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378557A (en) * 1963-06-04 1968-04-16 Searle & Co 5-alkyl-2-amino-3-aminoalkyl-6-aryl-4(3h)-pyrimidinones and congeners
GB2048250A (en) * 1979-03-19 1980-12-10 Upjohn Co 2-amino-6-aryl-4-pyrimidinols and their pharmaceutical uses
US4308272A (en) * 1980-10-03 1981-12-29 The Upjohn Company Process for treating hypertension
GB2107309A (en) * 1981-08-28 1983-04-27 Egyt Gyogyszervegyeszeti Gyar Preparation of 2-amino-4- hydroxy-5-halo-substituted pyrimidine derivatives
GB2158068A (en) * 1984-04-26 1985-11-06 Aston Molecules Ltd Pyrimidine derivative solvate compounds
JPS61205260A (ja) * 1985-03-08 1986-09-11 Zeria Shinyaku Kogyo Kk 新規な２−置換アミノ−６−（２−メトキシフエニ−ル）−４（３ｈ）−ピリミドン誘導体及びその製造法
US4689328A (en) * 1985-12-31 1987-08-25 Research Corporation Process for controlling hyperlipidemia
JPH0331267A (ja) * 1989-06-28 1991-02-12 Morishita Pharmaceut Co Ltd ２―アニリノ―１，６―ジヒドロ―６―オキソ―４―ピリミジンカルボン酸誘導体
WO1997033883A1 (fr) * 1996-03-13 1997-09-18 Smithkline Beecham Corporation Nouveaux composes de pyrimidine utiles dans le traitement de maladies a mediation cytokine
WO1997044326A1 (fr) * 1996-05-23 1997-11-27 F. Hoffmann-La Roche Ag Derives d'aryl pyrimidine
WO1998014504A1 (fr) * 1996-10-04 1998-04-09 Dsm N.V. Polymere supramoleculaire
WO1998018782A1 (fr) * 1996-10-28 1998-05-07 Celltech Therapeutics Limited Derives de 2-pyrimidineamine et procedes de preparation
WO1998025596A2 (fr) * 1996-12-12 1998-06-18 Pharmacia & Upjohn Company Methode de traitement de la sclerose en plaques

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
A. M. EL-REEDY ET AL., JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 26, no. 2, 1989, pages 313 - 6, XP000929372 *
F. A. ATTABY ET AL., ARCH. PHARMACAL RES., vol. 20, no. 6, 1997, pages 620 - 8, XP000864772 *
J. F. W. KEANA ET AL., JOURNAL OF ORGANIC CHEMISTRY, vol. 41, no. 12, 1976, pages 2124 - 9, XP002143538 *
J. M. PARMAR ET AL., INDIAN JOURNAL OF CHEMISTRY, vol. 38b, no. 4, April 1999 (1999-04-01), pages 440 - 4, XP000864783 *
M. F. M. HASSAN ET AL., CHINESE JOURNAL OF CHEMISTRY, vol. 9, no. 3, 1991, pages 262 - 9, XP000925588 *
M. FURUKAWA ET AL., CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 31, no. 7, 1983, pages 2473 - 9, XP002143539 *
N. H. ESHBA, ALEXANDRIA JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 9, no. 1, 1995, pages 31 - 4, XP000864773 *
N. RASHED ET AL., JOURNAL OF THE CHINESE CHEMICAL SOCIETY, vol. 40, no. 4, 1993, Taipei, pages 393 - 7, XP000864792 *
PATENT ABSTRACTS OF JAPAN vol. 11, no. 38 (C - 401) 4 February 1987 (1987-02-04) *
PATENT ABSTRACTS OF JAPAN vol. 15, no. 154 (C - 0825) 18 April 1991 (1991-04-18) *
S. A. ABDEL-AZIZ ET AL., PHOSPHORUS, SULFUR AND SILICON, vol. 113, no. 1-4, 1996, pages 67 - 77, XP000864775 *
S. KAMBE ET AL., SYNTHESIS, no. 4, 1979, pages 287 - 9, XP000929368 *
S. M. HUSSAIN ET AL., JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 22, no. 1, 1985, pages 169 - 71, XP000929371 *
S. M. HUSSAIN ET AL., JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 24, no. 6, 1987, pages 1605 - 10, XP000929369 *
V. J. RAM ET AL., EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 25, no. 6, 1990, pages 533 - 8, XP000929367 *
V. J. RAM ET AL., JOURNAL FÜR PRAKTISCHE CHEMIE, vol. 332, no. 5, 1990, pages 629 - 39, XP000864779 *
V. J. RAM ET AL., JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 21, no. 5, 1984, pages 1307 - 12, XP000929370 *
V. J. RAM ET AL., LIEBIGS ANNALEN DER CHEMIE, no. 9, 1987, pages 797 - 801, XP000929326 *
V. J. RAM, ARCHIV DER PHARMAZIE, vol. 323, no. 11, 1990, pages 895 - 9, XP000864784 *
V. J. RAM, JOURNAL FÜR PRAKTISCHE CHEMIE, vol. 331, no. 6, 1989, pages 893 - 905, XP000864780 *
V. J. RAM, JOURNAL FÜR PRAKTISCHE CHEMIE, vol. 331, no. 6, 1989, pages 957 - 63, XP000864778 *

Also Published As

Publication number Publication date
JP2002535318A (ja) 2002-10-22
WO2000043373A2 (fr) 2000-07-27
EP1144390A2 (fr) 2001-10-17
AU2734400A (en) 2000-08-07
AU768201B2 (en) 2003-12-04
CA2359680A1 (fr) 2000-07-27

Similar Documents

Publication Publication Date Title
WO2000043373A3 (fr) Inhibiteurs de kinase
CA2400447A1 (fr) Inhibiteurs de kinases
ATE396978T1 (de) Triazin-kinase-hemmer
WO2001060814A3 (fr) Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
WO2006050109A3 (fr) Nouveaux inhibiteurs de kinase
WO2007079164A3 (fr) Inhibiteurs de protéines kinases
WO2002096361A3 (fr) Derives de 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone utilises comme inhibiteurs de kinase
WO2004105700A3 (fr) Composes, procedes et compositions pharmaceutiques destines a l'inhibition de la parp
WO2004058769A3 (fr) Compositions utiles en tant qu'inhibiteurs des proteine kinases
WO2002076976A3 (fr) Inhibiteurs de rho-kinase
WO2002076977A3 (fr) Inhibiteurs de rho-kinase
WO2004031401A3 (fr) Nouveaux inhibiteurs de tyrosine kinases
WO2002044183A3 (fr) Composes et leurs utilisations
MXPA02005844A (es) Inhibidores de cinasas de proteina.
EP1485381B8 (fr) Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
WO2004030620A3 (fr) Inhibiteurs de tyrosine kinase
YU84603A (sh) Novi inhibitori tirozin kinaze
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
WO1999043651A3 (fr) Inhibiteurs d'enzymes phospholipases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2005105780A3 (fr) Compositions utiles en tant qu'inhibiteurs de la rock et d'autres proteines kinases
WO2004005281A8 (fr) Inhibiteurs de tyrosine kinases
WO2003051366A3 (fr) Inhibiteurs de kinase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 27344/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2000 594789

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2359680

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2359680

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007398

Country of ref document: MX

Ref document number: 2000905700

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000905700

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000905700

Country of ref document: EP